Patient‐reported outcomes with cemiplimab monotherapy for first‐line treatment of advanced non–small cell lung cancer with PD‐L1 of ≥50%: The EMPOWER‐Lung 1 study

Mahmut Gümüş; C. Chen; Cristina Ivanescu; Saadettin Kılıçkap; Igor Bondarenko; Mustafa Özgüroğlu; Miranda Gogishvili; Hacı Mehmet Türk; İrfan Çiçin; James Harnett; Vera Mastey; Ulrike Naumann; Matthew Reaney; Gerasimos Konidaris; Medha Sasané; Keri J. S. Brady; Siyu Li; Giuseppe Gullo; Petra Rietschel; Ahmet Sezer

doi:10.1002/cncr.34477

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Results support cemiplimab for first-line therapy of advanced NSCLC from the patient's perspective. Improved survival is accompanied by improvements versus platinum-doublet chemotherapy in GHS/QOL and functioning and reduction in symptom burden.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Gümüş et al. (2022) studied this question.

synapsesocial.com/papers/69d91c26f20ef263306841b8 https://doi.org/10.1002/cncr.34477

View Full Paper

Ask AI

Bookmark

Share

Patient‐reported outcomes with cemiplimab monotherapy for first‐line treatment of advanced non–small cell lung cancer with PD‐L1 of ≥50%: The EMPOWER‐Lung 1 study

Ask about this paper

Abstract

Discussion

Cite This Study

Patient‐reported outcomes with cemiplimab monotherapy for first‐line treatment of advanced non–small cell lung cancer with PD‐L1 of ≥50%: The EMPOWER‐Lung 1 study

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading